Réamhrá: Tá nasc fíor-riachtanach i dtaighde leighis, is é sin, turgnaimh ainmhithe. De réir staitisticí neamhiomlána, bíonn na milliúin ainmhithe ar fud an domhain thíos le turgnaimh eolaíocha gach bliain. Cé go bhfuaimeann sé fuilteach, is próiseas é freisin nach mór forbairt leighis a dhéanamh. Mar sin féin, le forbairt na teicneolaíochta bithphriontála 3d le blianta beaga anuas, táthar ag súil go mbainfidh roinnt tógálacha bithphriontáilte athsholáthar feidhmiúil fíocháin bheo, agus de réir a chéile a bhaint amach an cuspóir chun turgnaimh ainmhithe a athsholáthar.
△In 2014, about 400,000 mice died in the laboratory
18 Feabhra 2022 Tá tionscadal arna mhaoiniú ag an Aontas Eorpach (AE)-ag féachaint le laghdú a dhéanamh ar thástáil ainmhithe i dtaighde míochaine turgnamhach trí bhithphriontáil 3D. Arna chomhordú ag Institiúid Bith-innealtóireacht na Catalóine (IBEC), tá an tionscadal BRIGHTER (Bithphriontáil le Fótailiteagrafaíocht: Innealtóireacht Fíocháin Choimpléascach ag Ardtaifigh agus Luas) ag forbairt cineálacha cur chuige nua d’innealtóireacht fíocháin agus leigheas athghiniúnach 3D próisis bhithphriontáil 3D chun úsáid tacsaithe a laghdú i. na ceantair seo. Díol suntais go háirithe, díríonn an tionscadal ar dhéantús an chraiceann daonna trí úsáid a bhaint as teicníocht nua bithphriontála atá bunaithe ar leatháin solais léasair le patrún.
Professor Elena Martinez, coordinator of the BRIGHTER project, said: "Our innovative 3D bioprinting system not only achieves tissue closer to the real thing, but is also much faster than current systems, an essential factor in ensuring the viability of new tissue."
△ A small square containing a matrix of skin cells. Photo via IBEC.
Tástáil ainmhithe a laghdú le priontáil 3D
Tá dul chun cinn suntasach tagtha ar theicneolaíocht bhithphriontála 3D le deich mbliana anuas, agus tá dul chun cinn mór déanta maidir le fíocháin othair shainiúla inmharthana a fhorbairt. Cé go bhfuil geallúint ag na forbairtí seo do thrialacha éifeachtúlachta sa todhchaí, tá na fíocháin fós turgnamhach den chuid is mó, agus trialacha drugaí daonna fiche nó tríocha bliain ar shiúl. Mar sin féin, tá an saol acadúil agus an tionscal araon ag obair chun é sin a athrú, agus an déantóir bithphriontálaithe Sualannach CELLINK ag gealladh a thaighde ar mhúnlaí tástála cille neamhdhíobhálach d’ainmhithe a chur chun cinn agus ag baint úsáide as mionsamhlacha craiceann ag Ollscoil Stuttgart chun éifeachtúlacht drugaí ailse a thástáil d’fhonn deireadh a chur leis. tástáil ainmhithe.
Elsewhere, Fluicell's Biopixlar platform has produced highly complex neural models that show potential for future clinical drug screening applications, while UpNano's NanoOne Bio system is focusing on the fabrication of cell culture microstructures that may have Helps reduce the number of animal experiments behind clinical trials.
△CELLINK has acquired in vitro technology specialist MatTek to create a harmless drug testing model. Photo via MatTek.
Rogha níos daonnachtúla ar thástáil ainmhithe
In addition to IBEC, the Goethe University Frankfurt, the Technion Center in Israel and the biotechnology companies Mycronic and Cellendes are also participating in the BRIGHTER project. The program hopes to overcome many of the technical barriers that currently limit the fabrication of complex human tissue. The partners are collaborating on the development of a novel light-sheet bioprinting process capable of producing complex and accurate in vitro models that can be used for cosmetic and drug testing in the pharmaceutical industry and research settings. To fine-tune the technology, the BRIGHTER team is working to 3D print human skin, a highly complex tissue composed of multiple cell types and structures, such as sweat glands and hair follicles. Hydrogels will form a key component of the bioprinting process, as they form the basis for cells to grow and form new tissues, and they can also be personalized using a patient's own cells. To print skin with the desired structure, shape, and consistency, the researchers are using advanced imaging techniques that combine illumination from light sheets and high-resolution digital masks. By applying the laser directly to the hydrogel, the cells within it can be "patterned" and shaped into the right shape, allowing the team to control the stiffness, shape and size of the 3D printed structures.
The ability to shape hydrogels at a high level is especially critical for successfully printing human skin, because this tissue is made up of many layers of cells of different types. According to the BRIGHTER team, their bioprinting process was also able to create the blood vessels of the printed tissue and enable the function of sebaceous and sweat glands, as well as hair follicles to grow hair. Dr Nuria Torras, a postdoctoral researcher at IBEC, said: "We hope to be able to print a skin sample with an area of 1 square centimeter and a thickness of 1 mm in about 10 minutes with a cell viability rate of over 95 percent , greatly improving current bioprinting conditions. "The BRIGHTER project hopes that successful printing of the in vitro skin model will validate its potential for use in pharmaceutical and research settings, and ultimately reduce animal testing for drug and cosmetic testing.
Tá Teicneolaíocht Guangmai ag gabháil go mór le foinsí solais sláintiúla agus cliste, ag soláthar raon iomlán de tháirgí UVA UVB UVC LED, infridhearg IR LED VCSEL agus réitigh don mhargadh. Tá na céadta comhpháirtithe ardchaighdeáin aige i margaí baile agus eachtrannacha chun úsáid na teicneolaíochta solais a chur chun cinn le chéile chun saol sláintiúil agus cliste a chruthú. .
